Acquisition - Narrative (Details) - Kezar Life Sciences, Inc. $ / shares in Units, $ in Millions |
May 11, 2026
USD ($)
$ / shares
|
|---|---|
| Asset Acquisition [Line Items] | |
| Cash paid per acquiree share (in dollars per share) | $ / shares | $ 6.955 |
| Net cash acquired, threshold percentage | 100.00% |
| Net cash acquired, threshold amount | $ 50.0 |
| Contingent consideration, liability | $ 3.7 |
| X | ||||||||||
- Definition Asset Acquisition, Closing Net Cash Acquired Threshold Amount No definition available.
|
| X | ||||||||||
- Definition Asset Acquisition, Percent Interest Of Closing Net Cash Acquired Above Threshold No definition available.
|
| X | ||||||||||
- Definition Asset Acquisition, Price Per Share No definition available.
|
| X | ||||||||||
- Definition Amount of liability recognized from contingent consideration in asset acquisition. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|